Citigroup
NAMS icon

Citigroup’s NewAmsterdam Pharma NAMS Stock Holding History

Citigroup’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$272K Buy
8,026
+3,260
+68% +$107K ﹤0.01% 4183
2026
Q1 		$153K Buy
4,766
+1,068
+29% +$34.8K ﹤0.01% 4116
2025
Q4 		$130K Sell
3,698
-1,404
-28% -$51.1K ﹤0.01% 4198
2025
Q3 		$145K Buy
5,102
+355
+7% +$8.51K ﹤0.01% 4125
2025
Q2 		$86K Buy
4,747
+1,130
+31% +$20.6K ﹤0.01% 4483
2025
Q1 		$74K Sell
3,617
-1,043
-22% -$23.2K ﹤0.01% 4749
2024
Q4 		$120K Buy
+4,660
New +$99K ﹤0.01% 4746

Other funds holding NAMS

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
SAM
SEB Asset Management Stockholm $26.6B AUM
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Citigroup's NAMS Position: Q2 2026 in Review

Citigroup increased its NewAmsterdam Pharma (NAMS) stake by 68% in Q2 2026, buying an estimated $107K and bringing the position to 8,026 shares worth $272K. The position accounts for ﹤0.01% of the portfolio, ranked #4183.

Citigroup first reported a position in NAMS in Q4 2024 and has held it in 7 quarters since. 66 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

  • Citigroup held 8,026 shares of NewAmsterdam Pharma worth $272K as of Q2 2026.
  • Citigroup bought 3,260 NewAmsterdam Pharma shares in Q2 2026, an estimated $107K.
  • NewAmsterdam Pharma made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #4183 holding.
  • Citigroup first reported a position in NewAmsterdam Pharma in Q4 2024 and has held it in 7 quarters since.
  • 66 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.